Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505552 | 1.00 | IRAK4 (0.54) | IRAK4GAAALDH1A1HPGDHRH3 | |
| SCHEMBL16896618 | 0.86 | IRAK4 (0.61) | IRAK4GAAALDH1A1HPGDHRH3 | |
| SCHEMBL29662196 | 0.86 | IRAK4 (0.61) | IRAK4GAAALDH1A1HPGDHRH3 | |
| SCHEMBL18243749 | 0.85 | IRAK4 (0.48) | IRAK4GAAALDH1A1HPGDHRH3 | |
| SCHEMBL28376252 | 0.84 | IRAK4 (0.49) | IRAK4GAAALDH1A1HPGDHRH3 | |
| SCHEMBL16896583 | 0.83 | IRAK4 (0.72) | IRAK4IRAK1HDAC6NPC1RAB9A | |
| SCHEMBL29505540 | 0.83 | IRAK4 (0.72) | IRAK4IRAK1HDAC6NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL16896538 | 0.83 | IRAK4 (0.54) | IRAK4IRAK1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL29505505 | 0.83 | IRAK4 (0.54) | IRAK4IRAK1NPC1RAB9A | |
| SCHEMBL16896463 | 0.83 | HRH3 (0.46) | IRAK4GAAALDH1A1HPGDHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2025-11-27 | — | — | US | claimed |
| US-12178821-B2 | Combination therapies for the treatment of cancer | CURIS, INC. (US) | 2024-12-31 | — | — | US | claimed |
| US-20240294547-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2024-09-05 | — | — | US | claimed |
| US-20230414582-A1 | METHODS OF TREATING DISEASES AND DISORDERS | CURIS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4252853-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Aurigene Oncology Limited (IN) | 2023-10-04 | — | — | EP | claimed |
| EP-4248212-A1 | METHODS OF TREATING DISEASES AND DISORDERS | Curis, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| EP-3600270-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE ONCOLOGY LTD (IN) | 2023-06-14 | — | — | EP | claimed |
| US-20220339161-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-10-27 | — | — | US | claimed |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-08-23 | — | — | US | claimed |
| WO-2022108996-A1 | METHODS OF TREATING DISEASES AND DISORDERS | CURIS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| EP-3600270-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | Aurigene Discovery Technologies Limited (IN) | 2020-02-05 | — | — | EP | claimed |
| EP-3466955-A1 | METHOD OF PREPARING OXAZOLO[4,5-B]PYRIDINE AND THIAZOLO[4,5-B]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS FOR TREATING CANCER | Aurigene Discovery Technologies Limited (IN) | 2019-04-10 | — | — | EP | claimed |
| US-20180370988-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-12-27 | — | — | US | claimed |
| WO-2018178947-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-10-04 | — | — | WO | claimed |
| EP-3094329-B1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2018-09-26 | — | — | EP | claimed |
| US-20180022758-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2018-01-25 | — | — | US | claimed |
| US-9732095-B2 | Bicyclic heterocyclyl derivatives as IRAK4 inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2017-08-15 | — | — | US | claimed |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2016-11-24 | — | — | US | claimed |
| EP-3094329-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2016-11-23 | — | — | EP | claimed |
| WO-2015104688-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-07-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294547-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885GAA 2541/4885ALDH1A1 3272/4885 |
| US-20230414582-A1 | METHODS OF TREATING DISEASES AND DISORDERS | IRAK4, IRAK3, IRAK2 | IRAK4 1/4885GAA 103/4885ALDH1A1 1923/4885 |
| US-20160340366-A1 | BICYCLIC HETEROCYCLYL DERIVATES AS IRAK4 INHIBITORS | IRAK4, IRAK1, IRAK3 | IRAK4 1/4885GAA 1854/4885ALDH1A1 2855/4885 |
| US-20180370988-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885GAA 2571/4885ALDH1A1 3410/4885 |
| US-20180022758-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885GAA 2571/4885ALDH1A1 3410/4885 |
| US-11419875-B2 | Compounds and compositions for treating hematological disorders | IRAK4, FLT3, IRAK3 | IRAK4 1/4885GAA 3302/4885ALDH1A1 1660/4885 |
| US-12178821-B2 | Combination therapies for the treatment of cancer | IRAK4, IRAK2, IRAK3 | IRAK4 1/4885GAA 2282/4885ALDH1A1 3275/4885 |
| US-20220339161-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISORDERS | IRAK4, FLT3, IRAK3 | IRAK4 1/4885GAA 3302/4885ALDH1A1 1660/4885 |
| US-20250361244-A1 | BICYCLIC HETEROCYCLYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | IRAK4 1/4885GAA 2541/4885ALDH1A1 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.